-

Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes.

As previously announced, in light of Hologic’s pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
Release Versions
English
$Cashtags
$HOLX
Hashtags
#earnings
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening...

Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic’s AI-Powered Mammography Technology Flagged a Third of Breast Cancer Cases Initially Interpreted as Negative in Study of 7,500 Screening Exams...

New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy Duration

MARLBOROUGH, Mass.--(BUSINESS WIRE)--New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test...
Back to Newsroom